E525 | Jean Schmitt (Jolt Capital ) & Rob Blackie (Crampton Blackie): The State of RNA in Europe & the TechBio Opportunity
EUVC · EUVC
Audio is streamed directly from the publisher (anchor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this week's podcast,
is joined by
at
and
at
to explore one of the most consequential deep tech opportunities Europe faces: RNA. With roots in foundational biology and applications from cancer therapy to precision agriculture, RNA is both a symbol and a stress test of Europe’s capacity to scale science into sovereignty.
The conversation is based on their
on the State of RNA in Europe, a data-rich, in-depth analysis of patents, funding flows, regulatory bottlenecks, and startup activity across the continent.
Here’s what’s covered:
- 03:05 The State of RNA in Europe
- 05:59 Challenges in Commercialization and Investment
- 09:09 The Landscape of RNA Companies in Europe
- 15:02 Regulatory Challenges in RNA Development
- 17:58 The Future of RNA in Europe
- 26:54 Navigating Regulatory Challenges in Biocontrol Products
- 30:46 The Impact of European Policies on Innovation
- 32:41 Learning from Global Regulatory Practices
- 40:34 The Exodus of Talent and Innovation from Europe
- 45:59 Funding Challenges for RNA Companies in Europe